Tonantzin Matheus, MD
Gastroenterology · Lakewood Ranch, FLNPI 1629245683
Payments from drug & device makers
Across 314 payments — averaging $24.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$976
- Johnson & Johnson$781
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$472
- Pfizer$454
- Madrigal Pharmaceuticals$362
- plus $2K from 32 others
What the payments were for
- Consulting fees$210%
- Speaking & faculty fees$4155%
- Food & beverage$6,88191%
- Education$2844%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 99 | $2,151 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $976 |
| Johnson & Johnson | 23 | $781 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $472 |
| Pfizer | 26 | $454 |
| Madrigal Pharmaceuticals | 7 | $362 |
| Ardelyx, Inc. | 17 | $300 |
| QOL Medical, LLC | 9 | $222 |
| Axonics, Inc. | 5 | $219 |
| Ironwood Pharmaceuticals, Inc | 7 | $140 |
| Medtronic | 1 | $127 |
| Dilon Technologies, Inc. | 1 | $127 |
| Olympus America Inc. | 1 | $125 |
| Shionogi Inc | 5 | $118 |
| E.r. Squibb & Sons, L.L.C. | 2 | $112 |
| Aimmune Therapeutics, Inc. | 5 | $95 |
| Boston Scientific | 4 | $85 |
| Regeneron Healthcare Solutions, Inc. | 3 | $77 |
| Merck | 4 | $75 |
| Intercept Pharmaceuticals, Inc. | 5 | $65 |
| Bristol Myers Squibb | 3 | $64 |
| Lilly USA, LLC | 3 | $63 |
| Phathom Pharmaceuticals, Inc. | 4 | $53 |
| Amgen | 3 | $49 |
| Vivus LLC | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| AstraZeneca | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Organon | 2 | $22 |
| Novo Nordisk | 1 | $21 |
| Lucid Diagnostics Inc. | 1 | $20 |
| UCB, Inc. | 1 | $18 |
| Capsovision, Inc. | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $14 |
| Romark Laboratories, LC | 2 | $13 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Amitiza$415
- Skyrizi$231
- Rinvoq$207
- REZDIFFRA$138
- EndoFlip$127
- HemoBlast Bellows$127
- DISPOSABLE TRIPLE LUMEN SPHINCTEROTOME$125
- Single Use Electrosurgical Knife KD-655$125
- Tremfya$122
- Axonics$110
How this compares
$7,600 in reported general payments places this provider in the 65th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 111 | $105,045 |
| ZenpepLipase/Protease/Amylase | 15 | $98,777 |
| CreonLipase/Protease/Amylase | 14 | $64,537 |
| VoqueznaVonoprazan Fumarate | 17 | $19,787 |
| WegovySemaglutide | 13 | $17,015 |
| XifaxanRifaximin | 11 | $15,646 |
| Lubiprostone | 67 | $13,438 |
| Dexlansoprazole DrDexlansoprazole | 28 | $12,990 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 59 | $10,150 |
| MovantikNaloxegol Oxalate | 19 | $8,859 |
| Pantoprazole Sodium | 422 | $5,995 |
| Esomeprazole Magnesium | 84 | $5,149 |
| Budesonide DrBudesonide | 16 | $4,344 |
| Colestipol Hcl | 66 | $4,165 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 38 | $2,395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $2,151 | $169,582125 claims |
| Aimmune Therapeutics, Inc.Zenpep | $95 | $98,77715 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $53 | $19,78717 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $472 | $17,38423 claims |
| Novo NordiskWegovy | $21 | $17,01513 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $15 | $10,15059 claims |
| Redhill Biopharma Inc.Movantik | $17 | $8,85919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Lakewood Ranch
- Arun KhazanchiLakewood Ranch$1.4M
- Howard SchwartzTavernier$38.8M
- Guy NeffSarasota$17.6M
- Syed LateefClermont$6.4M
- Jeffrey SchneiderCoral Springs$6M
- Zaid RanaMiami$5.4M
- David NelsonGainesville$5.2M
- Alan WeintraubTampa$4.7M
- Curtis FreedlandNew Port Richey$4.5M
- Paul HellsternCrystal River$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.